-Re-expression of CD44+ in prostate cancer-Inhibition of clonogenic tumor cell growth and invasion-Apoptosis induction-Blockage of cell cycle in G1 and G2/M phases- Silencing NOTCH signaling pathway causes the downregulation of BCL-2 -Suppression of cell proliferation. Here, CD44 is linked to prostate carcinoma.